
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZNF710 (zinc finger protein 710) encodes a predicted nuclear zinc finger transcription factor with sequence-specific DNA-binding activity at RNA polymerase II cis-regulatory regions. The protein is predicted to regulate RNA polymerase II-dependent transcription and may influence expression of target genes through DNA-associated regulatory interactions. Its specific transcriptional targets, molecular partners, and biological functions remain incompletely characterized.
A human hepatocellular carcinoma model, MHCC97-H was established from a highly metastatic human hepatocellular carcinoma and selected for its invasive and metastatic phenotype. The cells originated from a liver tumor of a 39-year-old male and are classified as a human liver cancer cell line. MHCC97-H is characterized by a hypotriploid karyotype and has been used in studies of hepatocellular carcinoma invasion and metastasis.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_198526
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?